HBs Ab
Enzyme ImmunoAssay (ELISA) for both the quantitative and qualitative determination of antibodies to the Surface Antigen of Hepatitis B Virus in human plasma and sera.
“Hepatitis B is one of the major diseases of mankind and is a serious global public health problem. Hepatitis means inflammation of the liver, and the most common cause is infection with one of 5 viruses, called hepatitis A,B,C,D, and E. All of these viruses can cause an acute disease with symptoms lasting several weeks including yellowing of the skin and eyes (jaundice); dark urine; extreme fatigue; nausea; vomiting and abdominal pain. It can take several months to a year to feel fit again. Hepatitis B virus can cause chronic infection in which the patient never gets rid of the virus and many years later develops cirrhosis of the liver or liver cancer. HBV is the most serious type of viral hepatitis and the only type causing chronic hepatitis for which a vaccine is available. Hepatitis B virus is transmitted by contact with blood or body fluids of an infected person in the same way as human immunodeficiency virus (HIV), the virus that causes AIDS. However, HBV is 50 to 100 times more infectious than HIV. The main ways of getting infected with HBV are: (a) perinatal (from mother to baby at the birth); (b) child- tochild transmission; (c) unsafe injections and transfusions; (d) sexual contact.
Microplates are coated with a preparation of highly purified HBsAg that in the first incubation with sample specifically captures anti HBsAg antibodies to the solid phase.
After washing, captured antibodies are detected by an HBsAg, labelled with peroxidase (HRP), that specifically binds the second available binding site of these antibodies. The enzyme specifically bound to wells, by acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of HBsAb in the sample and can be detected by an ELISA reader.
The amount of antibodies may be quantitated by means of a standard curve calibrated against the W.H.O reference preparation.
Samples are pre treated in the well with an specimen diluent able to block interference present in vaccinated individuals.
- Engvall E. et al., J.Immunochemistry, 8, 871-874, 1971.
- Engvall E. et al., J.Immunol. 109, 129-135, 1971.
- Remington J.S. and Klein J.O. In “Infectious diseases of the fetus and newborn infant”. Sanders, Philadelphia, London, Toronto.
- Volk W.A. In “Essential of Medical Microbiology”. 2nd ed., pp 729, G.B.Lippincott Company, Philadelphia, New York, S.Josè, Toronto
- Snydman D.R. et al., Ann.Int.Med., 83 : 838, 1975.
- Barker L.F., Dodd R.J., Sandler S.G.. In “viral Hepatitis: Laboratory and Clinical Science” F.Deinhardt, J. Deinhardt eds., M.Dekker Inc., New York, 215-230, 1983.
- Cossart Y., Brit.Med.Bull., 28: 156, 1972
- Lander J.J. et al., J.Immunol., 106: 1066, 1971
- Mushawar I.K. et al.. Ann.J.Clin.Pathol., 76: 773, 1981. 10. Howard C.R., Immunol.Today, 5: 185, 1984